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volume on day 1 demonstrated a failure to collect 2x106
CD34/kg recipient weight in 2/15 donors (13.3%). The mean
CD34/Kg recipient weight collected from these donors was
3.97 x 106 CD34/Kg. No donor regardless of day one
apheresis volume failed to reach this goal after two days of
apheresis.
All recipients engrafted. The median time to neutrophil
engraftment was 13 days (range 11 - 22 days), and median
time to platelet engraftment >50K was 24 days (range 15 -
106). 14/18 (78%) recipients had 100% donor chimerism at
day 30 post transplant. Of the 14 evaluable recipients
receiving mobilized products from donors mobilized with
5mcg/kg GM-CSF+plerixafor, the incidence of grades IIeIV
and III-IV acute GvHD was 35.7% and 21.2%. Of all evaluable
recipients (n¼18) treated on study, the incidence of grades II-
IV and III-IV acute GvHD were 44% and 22.2%. The incidence
of cGvHD for all recipients surviving past 100 days (n ¼ 13)
was 61.5%. CMV viremia occurred in 10/15 (66.6%) of re-
cipients and CMV disease was identiﬁed or suspected in 5/15
(33.3%).
GM-CSF at 5mcg/kg combined with IV plerixafor is a feasible
combination to overcome low apheresis CD34 yields
observed with either agent alone. Phenotypic and functional
studies of cellular graft content are ongoing.33
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Known CMV 8 (12) 0 7 (33) 0
RSV 2 (3) 1 (1) 0 0
PIV 2 (3) 0 0 0
HMPV 2 (3) 2 (3) 0 0
Aspergillus 8 (12) 1 (1) 3 (14) 0
Unknown HHV6 20 (29) 4 (6) 1 (5) 0
HRV 8 (12) 6 (9) 1 (5) 0
Kl 3 (4) 1 (1) 5 (24) 0
WU 1 (1) 0 0 0
CoV 0 0 1 (5) 1 (5)
HSV 2 (3) 0 0 0
EBV 1 (1) 0 2 (10) 0
BK 3 (4) 0 0 0
The values indicate the total number of patients (percentage of detected
patients).
* High load: >100,000 copies/ml, <32 cycle threshold (HRV) or co-detection
of a GM in serum.Center Hospital, Tokyo, Japan; 9Laboratory Medicine,
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Background: Idiopathic pneumonia syndrome (IPS) is
diagnosed by clinical/radiographic presentation and the
exclusion of infection. However, molecular diagnostic
methods may allow cases previously classiﬁed as idiopathic
to be linked to an infectious agent. We applied a broad panel
of currently available molecular tests and pathogen discov-
ery methods to patients with IPS and correlated pathogen
detection with outcome.
Methods: Frozen bronchoalveolar lavage (BAL) samples
from 69 HCT patients with IPS diagnosed from 1992 to
2006 were tested by Q-PCR for Legionella, M. pneumoniae,
C. pneumoniae, HSV, VZV, EBV, CMV, HHV-6, polyomavirus
(BK, JC, WU, KI), parvovirus B19, RSV, PIV, Inﬂuenza, HMPV,
ADV, HRV, CoVs, HBoV, Enterovirus and Parechovirus, and
for aspergillus GM (aGM). Research BALs obtained between
day 35 and 50 from 21 asymptomatic HCT patients served
as controls. Pathogens were categorized by quantity and
known/unknown pathogenicity; the association with
overall mortality was analyzed using Cox regression
models.
Results: Among 69 HCT patients with IPS (time from HCT to
BAL: median 22 days, range 4e119), 39 (57%) had a pathogen
detected, compared to 11 out of 21 controls (52%); high
pathogen load was detected in 19% and 5%, respectively
(Table). The most frequent pathogens were HHV-6 and HRV;
CMV low-level shedding was also detected. Among the pa-
tients with IPS, the presence of a pathogen was associated
with higher mortality in multivariate models (HR, 1.92;
p¼0.03; adjusted for donor type, steroid use, and diffuse
alveolar hemorrhage); neither pathogenicity category
(Figure) nor pathogen loadwere signiﬁcantly associatedwith
mortality.
Conclusions: A signiﬁcant number of pathogens were
detected in patients with IPS, and pathogen detection was
associated with increased mortality. The increased mortality
could be due to lack of speciﬁc treatment and/or use of cor-
ticosteroids. Known pathogens (aspergillus, RSV, PIV, HMPV)
can now be readily detected by multiplex PCR and the aGM
assay. The interpretation of the detection of pathogens of
unknown signiﬁcance (HHV-6, HRV) is more difﬁcult, but
mortality was similar to that of known pathogens. Overall,
our data suggest that expanded infection detection panels
may re-classify a signiﬁcant number of IPS cases as infectious
pneumonia.
